NCT03204864 (Opsite 2) is a NA clinical trial of RLD Group in HF Patient, sponsored by Michele Brignole.

Who is sponsoring NCT03204864?

NCT03204864 is sponsored by Michele Brignole.

What drugs are being tested in NCT03204864?

Interventions in NCT03204864: RLD Group, Conventional CS lead placement.

What condition does NCT03204864 study?

NCT03204864 studies HF Patient.

Is NCT03204864 still recruiting?

NCT03204864 is currently completed. Last updated 11 September 2018.

Last reviewed 2018-09-11 · How we verify

NCT03204864: Opsite 2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimization of Coronary Sinus Lead Placement Targeted to the Longest Right-to-Left Delay

Completed NA Last updated 11 September 2018

What this trial tests

NA trial testing RLD Group in HF Patient in 211 participants. Completed in 31 March 2018.

Timeline

1 March 2016

Primary endpoint
30 September 2017

31 March 2018

Quick facts

Lead sponsor	Michele Brignole
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	211
Start date	1 March 2016
Primary completion	30 September 2017
Estimated completion	31 March 2018
Sites	4 locations across Italy

Drugs / interventions tested

RLD Group
Conventional CS lead placement

Conditions studied

HF Patient — all drugs for HF Patient →

Sponsor

Michele Brignole

Who can join

Eligibility, any sex, with HF Patient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multi-center, physician-initiated study, with intra-center control arm of patients with advanced heart failure undergoing cardiac resynchronization therapy (CRT) with or without defibrillator therapy. The purpose of this study is to verify whether optimizing the left ventricular lead position at implantation with the pacing cathode corresponding to the longest RV-to-LV electrical delay may result in a better patient outcome. The RV-to-LV electrical delay will be evaluated with RLD value (ms). RLD is the distance between the Right Ventricular pacing marker (VP) and the maximum peak (or the first maximum peak in case of two equally tall peaks) of the LV bipolar deflection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Optimization of coronary sinus lead placement targeted to right-to-left delay in patients undergoing cardiac resynchronization therapy.
Oddone D, Solari D, Arena G, Mureddu R, et al · · 2019 · cited 4× · PMID 30508076 · DOI 10.1093/europace/euy275

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03204864 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michele Brignole
Last refreshed: 11 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03204864.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing